VIP Nasal Spray for Chronic Inflammatory Response Syndrome (CIRS) with Dr. Scott McMahon

VIP Nasal Spray: A Targeted Peptide Therapy for CIRS

Vasoactive intestinal peptide (VIP) nasal spray sits in a unique position in the peptide therapy space. Unlike peptides used for muscle building or skin improvement, VIP is used to treat a specific, well-defined medical condition: Chronic Inflammatory Response Syndrome (CIRS). Dr. Scott McMahon, speaking with Strive Compounding Pharmacy, explains the clinical rationale and practical application of VIP in the Shoemaker Protocol, a structured treatment approach for patients whose immune systems have been thrown into chronic disarray by biotoxin exposure, most commonly from water-damaged buildings.

CIRS is a multi-system inflammatory condition triggered by exposure to biotoxins, with mold being the most common culprit. The defining feature of CIRS is that the inflammatory response does not resolve after the toxic exposure ends. In genetically susceptible individuals (roughly 24% of the population carries HLA-DR genes that impair biotoxin clearance), the immune system becomes locked in a chronic inflammatory state that affects virtually every organ system: neurological, respiratory, musculoskeletal, gastrointestinal, endocrine, and immunological.

Where VIP Fits in the Treatment Sequence

This is critically important and Dr. McMahon emphasizes it repeatedly: VIP nasal spray is not a first-line treatment for CIRS. It comes at the end of a multi-step protocol that must be followed in sequence. The Shoemaker Protocol involves roughly a dozen steps, starting with removal from the mold-contaminated environment and progressing through cholestyramine treatment (a bile acid sequestrant that binds biotoxins), correction of MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci, a deep nasal biofilm infection), normalization of specific biomarkers, and various other targeted interventions.

VIP is typically the last or near-last step in this protocol. The reasoning is practical: if you administer VIP while the patient is still being exposed to biotoxins, still has MARCoNS, or still has uncorrected upstream biomarkers, VIP will not work properly and may even worsen certain aspects of the condition. Each prior step in the protocol addresses a specific piece of the inflammatory puzzle, and VIP is designed to address the residual inflammation that persists after everything else has been corrected.

Specifically, VIP normalizes several biomarkers that are characteristically abnormal in CIRS patients: transforming growth factor beta-1 (TGF-beta 1), vascular endothelial growth factor (VEGF), C3a and C4a (complement system markers), and matrix metalloproteinase-9 (MMP-9). These markers reflect ongoing inflammatory activation across multiple pathways. VIP acts on receptors throughout the body (VPAC1 and VPAC2 receptors) to broadly suppress this multi-pathway inflammation in a way that individual anti-inflammatory medications cannot match.

The Mechanism of VIP in CIRS

Vasoactive intestinal peptide is a 28-amino acid peptide that is produced naturally throughout the body, with particularly high concentrations in the gut, brain, and lungs. It functions as a neurotransmitter, an immune modulator, and a vasodilator. In CIRS patients, VIP levels are often suppressed, which Dr. McMahon describes as both a consequence and a perpetuating factor of the chronic inflammatory state.

When administered as a nasal spray, VIP is absorbed through the nasal mucosa and enters systemic circulation. The nasal route provides relatively rapid absorption and avoids first-pass liver metabolism, which would significantly reduce the peptide's bioavailability if taken orally. The nasal spray format also makes self-administration practical for patients who need to use VIP daily over extended periods.

VIP's anti-inflammatory effects operate through several pathways simultaneously. It suppresses the production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12. It promotes the generation of regulatory T cells (Tregs), which are critical for preventing autoimmune responses and maintaining immune tolerance. It stabilizes mast cells, reducing histamine release and the allergic-type reactions common in CIRS patients. And it modulates the complement system, normalizing the elevated C3a and C4a levels that drive ongoing tissue inflammation.

Clinical Application and Monitoring

The typical VIP nasal spray protocol involves 4 sprays per day (50mcg per spray, total 200mcg daily) into each nostril. Treatment duration varies but commonly extends for 1 to 3 months initially, with monitoring of biomarkers to assess response. Some patients require longer courses, and a subset may benefit from periodic maintenance courses.

Before starting VIP, Dr. McMahon requires confirmation that MARCoNS has been eradicated. This is non-negotiable in his practice. MARCoNS is a biofilm-forming staphylococcal infection that colonizes the deep nasal passages and produces exotoxins that interfere with immune function, specifically melanocyte-stimulating hormone (MSH) levels. Administering VIP to a patient with active MARCoNS can theoretically worsen the infection by suppressing local immune activity in the nasal passages. The standard MARCoNS treatment involves BEG spray (Bactroban, EDTA, and gentamicin) for several weeks before a culture confirms eradication.

Monitoring during VIP treatment involves tracking the specific biomarkers it targets. TGF-beta 1, VEGF, C3a, C4a, and MMP-9 are measured before starting VIP and periodically during treatment. Visual contrast sensitivity (VCS) testing, a functional test that assesses neurological impact of biotoxin exposure, is also used to track clinical improvement. Symptom questionnaires provide subjective data on how patients are feeling.

Patient Response Patterns

Dr. McMahon describes several common response patterns. Some patients experience dramatic improvement within the first few weeks of VIP treatment, with significant reductions in fatigue, brain fog, joint pain, and respiratory symptoms. Others show a more gradual response over 2 to 3 months. A subset of patients show biomarker improvement on lab work before noticing subjective symptom improvement, while others feel better before their labs normalize.

A small percentage of patients experience a temporary worsening of symptoms when starting VIP, sometimes described as a "detox reaction" or Herxheimer-like response. Dr. McMahon attributes this to the rapid shift in immune activity as VIP suppresses chronic inflammation and the body begins processing accumulated inflammatory debris. These reactions are typically mild and self-limiting, resolving within a few days to two weeks. Reducing the dose temporarily and then gradually increasing is the standard management approach.

Treatment failure with VIP almost always traces back to incomplete completion of prior protocol steps. A patient who starts VIP while still being exposed to mold, or with untreated MARCoNS, or with uncorrected hormonal deficiencies, will not respond as expected. This is why Dr. McMahon insists on the sequential protocol approach rather than jumping to VIP as a standalone treatment.

Access, Cost, and Practical Considerations

VIP nasal spray is available through compounding pharmacies with a physician's prescription. It is not an FDA-approved drug for CIRS (or any indication), and it is not covered by insurance. The cost varies by pharmacy but typically runs $80 to $150 per month, plus the cost of the physician visits and laboratory testing required for proper monitoring. Over a treatment course of several months, the total cost can be significant.

Finding a physician knowledgeable about the Shoemaker Protocol and VIP therapy can be challenging. The Surviving Mold website maintains a list of certified practitioners, and some functional medicine physicians have training in this area. Attempting to use VIP without proper medical guidance and the full protocol context is strongly discouraged by Dr. McMahon. The treatment is safe when used appropriately but relies on accurate diagnosis, correct sequencing of prior treatments, and proper monitoring to be effective.

For patients who have completed the Shoemaker Protocol through the VIP step and achieved normalization of their biomarkers, the question of long-term management arises. Some patients maintain their improvements indefinitely after a single course of VIP. Others experience gradual recurrence of symptoms and biomarker elevations and benefit from periodic "maintenance" courses of VIP once or twice a year. Continued avoidance of biotoxin exposure remains the foundation of long-term management, with VIP serving as a targeted intervention when inflammatory markers begin to drift.

The broader significance of VIP in the peptide therapy world is its demonstration that peptides can address complex, multi-system inflammatory conditions in a way that conventional single-pathway medications cannot. CIRS involves dysfunction across the complement system, cytokine networks, hormonal axes, and neurological pathways simultaneously. VIP's ability to modulate multiple inflammatory pathways through a single administration makes it uniquely suited to this type of condition, and it illustrates the therapeutic potential of peptides that work across biological systems rather than targeting a single receptor or pathway.

Dr. McMahon also addresses the relationship between VIP and the broader conversation about mold illness in the medical community. CIRS remains a somewhat controversial diagnosis in mainstream medicine, with some physicians questioning the validity of the Shoemaker Protocol and the biomarkers it uses. McMahon acknowledges this tension while pointing to the growing body of peer-reviewed publications supporting the biotoxin model of chronic illness and the specific biomarker abnormalities that VIP addresses. For patients navigating this space, the practical advice is to seek physicians who are both open to the CIRS diagnosis and rigorous in their diagnostic approach. A diagnosis of CIRS should be based on objective biomarker testing, more than symptom checklists, and treatment should follow the sequential protocol rather than jumping to whichever intervention sounds most appealing. VIP therapy is most effective and safest when it comes at the right point in a carefully executed treatment sequence.